Berlin (VFA) – What did two and a half years of the Grand Coalition do for Germany as a location for the pharmaceutical industry? To answer this question, the German Association of Research-based Pharmaceutical Companies (VFA) commissioned Prof. Dr. Thomas Straubhaar of the Hamburg Institute of International Economics (HWWI) to carry out a study reviewing the policy of the Grand Coalition in terms of Germany as a location for the pharmaceutical industry.

Prof. Straubhaar draws the following conclusions: "Overall, the measures of the Grand Coalition to benefit Germany as a location for the pharmaceutical industry are heading in the right direction. We must positively emphasize the various research initiatives, the promotion of excellence and – with a few exceptions – the corporate tax reform. Key weaknesses include the high, and in part contradictory, regulatory density as well as inefficient application and approval procedures. If Germany concentrates on its location-based advantages and makes their maintenance and targeted expansion the focus of a political strategy, it could become a globally leading location for the pharmaceutical industry again, even in view of increasing competition from emerging countries."

Dr. Wolfgang Plischke, chairman of the board of directors of the German Association of Research-based Pharmaceutical Companies: "In Germany alone, the pharmaceutical industry employs 112,600 people and generated sales worth EUR 31.2 billion in 2007. As a result, it is among the most efficient and productive industries in Germany. But, especially with managers in charge of site selection, Germany's esteem as a location for the pharmaceutical industry has suffered due to obscure and partly contradictory overregulation of the health care system. We should thin out the regulatory jungle, so that investors can find their way back to us."

"I primarily draw one conclusion from the study submitted by the HWWI: Germany is underselling itself as a location for the pharmaceutical industry. Nobody benefits from this fact – neither the pharmaceutical industry nor the politicians. Therefore, I am asking the German government to initiate an international site policy campaign together with the VFA that underscores the advantages of our location to those managers who are in charge of capital spending," Plischke added.

To access the digital press kit, please visit:
https://www.vfa.de/pk20080508

The German Association of Research-based Pharmaceutical Companies (VFA) is the trade association of the research-based pharmaceutical companies in Germany. It represents the interests of 43 globally leading research-based pharmaceutical companies and more than 100 subsidiaries and affiliated companies in the areas of health, research and economic policy. The VFA member companies make up about two-thirds of the German pharmaceutical market and employ nearly 78,000 people in Germany, including more than 18,000 in research and development. The VFA's press conferences – now available on the Internet. For more information, please visit: https://www.vfa.de/en/press/online-pk-akkreditierung-en.html


For more information, please contact:

Press Officer
Dr. Jochen Stemmler
Phone: +49 30 20604-203
Fax: +49 30 20604-209